EBOLA VACCINE

Merck’s Ebola Vaccine 84% effective in trial, suitable for prophylactic Use: GlobalData

According to GlobalData, vaccine effectiveness was estimated using odds ratio calculations, which determined that 10 days after vaccination, rVSV-ZEBOV was 80 per cent effective against the Ebola virus in females, 86 per cent in males, 80 per cent in children under 15 years of age, 83 per cent in adults aged 15 years or older, and overall, 84 per cent effective.

More in EBOLA VACCINE

Vaccine trials on Sudan Ebola strain to start in weeks - WHO chief

"Our primary focus now is to rapidly control and contain this outbreak to protect neighbouring districts as well as neighbouring countries." says health officials
Vaccine group announces creation of Ebola vaccine stockpile

GAVI is a public-private partnership that includes the World Health Organisation, UNICEF, the Bill & Melinda Gates Foundation and the World Bank, among others.
New Ebola vaccine found to be safe in humans: study

The trial involving about 40 healthy people aged between 18 and 65 years looked at the safety of the vaccine and the lowest dose required for an immune response after injection with one of three doses.
Ebola vaccine shows 100% results in trial

experimental Ebola vaccine tested on humans in the waning days of the West African epidemic has been shown to provide 100% protection against the lethal disease.
China to test its Ebola vaccine on humans

Scientists are racing to develop Ebola vaccines after the world's worst outbreak of the virus, which has killed more than 7,000 people in West Africa.